Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells.

Bhattacharya R, Ye XC, Wang R, Ling X, McManus M, Fan F, Boulbes D, Ellis LM.

Cancer Res. 2016 May 15;76(10):3014-24. doi: 10.1158/0008-5472.CAN-15-1605. Epub 2016 Mar 17.

PMID:
26988990
2.

Neuropilin-2 Regulates Endosome Maturation and EGFR Trafficking to Support Cancer Cell Pathobiology.

Dutta S, Roy S, Polavaram NS, Stanton MJ, Zhang H, Bhola T, Hönscheid P, Donohue TM Jr, Band H, Batra SK, Muders MH, Datta K.

Cancer Res. 2016 Jan 15;76(2):418-28. doi: 10.1158/0008-5472.CAN-15-1488. Epub 2015 Nov 11.

PMID:
26560516
3.

Neuropilin-2 Is a Newly Identified Target of PAX8 in Thyroid Cells.

Lucci V, Di Palma T, Zannini M.

PLoS One. 2015 Jun 1;10(6):e0128315. doi: 10.1371/journal.pone.0128315. eCollection 2015.

4.

Neuropilin-2 expression is inhibited by secreted Wnt antagonists and its down-regulation is associated with reduced tumor growth and metastasis in osteosarcoma.

Ji T, Guo Y, Kim K, McQueen P, Ghaffar S, Christ A, Lin C, Eskander R, Zi X, Hoang BH.

Mol Cancer. 2015 Apr 17;14:86. doi: 10.1186/s12943-015-0359-4.

5.

Preclinical and clinical development of siRNA-based therapeutics.

Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G.

Adv Drug Deliv Rev. 2015 Jun 29;87:108-19. doi: 10.1016/j.addr.2015.01.007. Epub 2015 Feb 7. Review.

PMID:
25666164
6.
7.

Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy.

Gowda R, Jones NR, Banerjee S, Robertson GP.

J Nanomed Nanotechnol. 2013 Dec;4(6). pii: 184.

8.

Liposomal siRNA nanocarriers for cancer therapy.

Ozpolat B, Sood AK, Lopez-Berestein G.

Adv Drug Deliv Rev. 2014 Feb;66:110-6. doi: 10.1016/j.addr.2013.12.008. Epub 2013 Dec 30. Review.

9.

VEGF targets the tumour cell.

Goel HL, Mercurio AM.

Nat Rev Cancer. 2013 Dec;13(12):871-82. doi: 10.1038/nrc3627. Review.

10.

Neuropilins: a new target for cancer therapy.

Grandclement C, Borg C.

Cancers (Basel). 2011 Apr 8;3(2):1899-928. doi: 10.3390/cancers3021899.

11.

miR-331-3p regulates expression of neuropilin-2 in glioblastoma.

Epis MR, Giles KM, Candy PA, Webster RJ, Leedman PJ.

J Neurooncol. 2014 Jan;116(1):67-75. doi: 10.1007/s11060-013-1271-7. Epub 2013 Oct 19.

12.

Neuropilin-2 Is upregulated in lung cancer cells during TGF-β1-induced epithelial-mesenchymal transition.

Nasarre P, Gemmill RM, Potiron VA, Roche J, Lu X, Barón AE, Korch C, Garrett-Mayer E, Lagana A, Howe PH, Drabkin HA.

Cancer Res. 2013 Dec 1;73(23):7111-21. doi: 10.1158/0008-5472.CAN-13-1755. Epub 2013 Oct 11. Erratum in: Cancer Res. 2014 Jan 15;74(2):637.

13.

Nanocarrier-mediated targeting of tumor and tumor vascular cells improves uptake and penetration of drugs into neuroblastoma.

Pastorino F, Brignole C, Loi M, Di Paolo D, Di Fiore A, Perri P, Pagnan G, Ponzoni M.

Front Oncol. 2013 Aug 5;3:190. doi: 10.3389/fonc.2013.00190. eCollection 2013.

14.

Recent developments in nanoparticle-based siRNA delivery for cancer therapy.

Lee JM, Yoon TJ, Cho YS.

Biomed Res Int. 2013;2013:782041. doi: 10.1155/2013/782041. Epub 2013 Jun 17. Review.

15.

Multimodality imaging of RNA interference.

Nayak TR, Krasteva LK, Cai W.

Curr Med Chem. 2013;20(29):3664-75. Review.

16.

Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial α5 integrin.

Cao Y, Hoeppner LH, Bach S, E G, Guo Y, Wang E, Wu J, Cowley MJ, Chang DK, Waddell N, Grimmond SM, Biankin AV, Daly RJ, Zhang X, Mukhopadhyay D.

Cancer Res. 2013 Jul 15;73(14):4579-90. doi: 10.1158/0008-5472.CAN-13-0529. Epub 2013 May 20.

17.

GLI1 regulates a novel neuropilin-2/α6β1 integrin based autocrine pathway that contributes to breast cancer initiation.

Goel HL, Pursell B, Chang C, Shaw LM, Mao J, Simin K, Kumar P, Vander Kooi CW, Shultz LD, Greiner DL, Norum JH, Toftgard R, Kuperwasser C, Mercurio AM.

EMBO Mol Med. 2013 Apr;5(4):488-508. doi: 10.1002/emmm.201202078. Epub 2013 Feb 21.

18.

Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer.

Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ, Mok SC.

Clin Cancer Res. 2013 Feb 15;19(4):809-20. doi: 10.1158/1078-0432.CCR-12-2736. Epub 2013 Jan 23.

19.

Enhancing integrin function by VEGF/neuropilin signaling: implications for tumor biology.

Goel HL, Mercurio AM.

Cell Adh Migr. 2012 Nov-Dec;6(6):554-60. doi: 10.4161/cam.22419. Epub 2012 Oct 17. Review.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk